A Study to Evaluate the Safety and Efficacy of AHB-137 in Healthy Participants and HBeAg-negative Chronic Hepatitis B (CHB) Patients

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of AHB-137 subcutaneous injection in healthy participants after single and multiple doses, and evaluate the preliminary efficacy of AHB-137 in CHB participants after up to 24 weeks of treatment as a proof-of-concept.

Timeline

Start

2023-08-03

Primary completion

2024-12-03

Completion

2025-11-10

Publications

• Wang W, Mai J, Hou J, Xu Z, Yu X, Ren H, Liang X, Yang Y, Liu Z, Zhang H, Zhong S, Wen Y, Lu T, Cao H, Qiu X, Wang L, Zhao D, Wang M, Yang C, Cheng G, Niu J, Ding Y. Safety, pharmacokinetics and antiviral activity of AHB-137 in healthy volunteers and chronic hepatitis B patients: a phase 1a/1b study. Hepatol Int. 2026 May 23. doi: 10.1007/s12072-026-11102-7. Online ahead of print.

Drugs

Indications